MHRA approves Pfizer-BioNTech vaccine for the UK, will be available from next week

December 02, 2020 07:21 PM AEDT | By Kunal Sawhney
 MHRA approves Pfizer-BioNTech vaccine for the UK, will be available from next week

In a historic development, the Medicines and Healthcare Products Regulatory Authority (MHRA) of the United Kingdom has given approval to the Pfizer-BioNTech vaccine. With this, the UK has become the first western country ahead of the US and Europe to approve a vaccine for mass immunisation. The MHRA was given the power to approve a suitable vaccine by the Boris Johnson government under special regulations before 1 January.

In a statement, the government has said that the vaccine will be available in the UK from next week. The UK has already bought 40 million doses. The vaccine which has to be kept at -70C, as per the company, can be stored for up to five days in a fridge, at an average temperature of 2 to 8°C.

A government spokesperson has said that the experts at MHRA have conducted various studies and concluded that the vaccine was apt and has met its strict standards of safety, quality and effectiveness.

He added that the MHRA officials would soon issue the next advisory on the vaccination process and the priority groups who would receive the vaccine. The first priority group includes care home residents, health and care staff, the elderly and others who are extremely vulnerable.

Earlier, Pfizer-BioNTech had claimed that their Covid-19 vaccine was safe and had 95 per cent efficacy and has claimed that it works well for older people who are most at risk of fatality due to the disease. Its final result had shown that in the final trial only eight of the 20,000 people who were given the vaccine got infected due to the coronavirus.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.